Depomed (DEPO) Misses Q1 EPS by 5c

Go back to Depomed (DEPO) Misses Q1 EPS by 5c

Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy

May 9, 2016 7:37 AM EDT

Mizuho Securities upgraded DepoMed Inc (NASDAQ: DEPO) from Neutral to Buy with a price target of $19.00 (from $18.00), on increased takeout probability.

Analyst Irina Koffler commented, "DEPO posted unimpressive numbers in 1Q:16 and shares got dragged down with the group on Friday.... More

DepoMed (DEPO) PT Lowered to $21 at Piper Jaffray

May 6, 2016 9:09 AM EDT

Piper Jaffray analyst David Amsellem lowered his price target on DepoMed Inc (NASDAQ: DEPO) to $21.00 (from $23.00) and reiterated a Overweight rating following Q1 results.

Amsellem commented, "Depomed reported adjusted diluted EPS of $0.12 on revenues of $105M, versus Street estimates of $0.17 and $107M, respectively... More